ASCO 2024: Belzutifan in Patients with Advanced Clear Cell R

ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).

Related Keywords

United States , Toronto , Ontario , Canada , Washington , Georgetown University , District Of Columbia , Chicago , Illinois , American , Michael Atkins , Michaelb Atkins , University Of Toronto , Georgetown Lombardi Comprehensive Cancer Center , Department Of Medical Oncology , Database Consortium , Twitter , Georgetown University Medical Center , Merck Sharp Dome , Society Of Urologic Oncology , International Metastatic , American Society Of Clinical Oncology , Clinical Oncology , Annual Meeting , Deputy Director , Scholl Professor , Vice Chair , Medical Oncology , Rashid Sayyid , Urologic Oncology , Clinical Fellow ,